Table 3 Study outcomes
From: Outcomes of arteriovenous access among cancer patients requiring chronic haemodialysis
Outcome | Total (N = 84) |
|---|---|
Uncensored primary patency | 34.3 months (95% CI, 26.9–41.7) |
Uncensored secondary patency | 46.1 months (95% CI, 37.5–54.7) |
Death-censored primary patency | 55.8 months (95% CI, 45.8–65.3) |
Death-censored secondary patency | 75.9 months (95% CI, 67.1–84.7) |
Early failure | 21* (25.0%) |
Patient death | 15* |
Maturation failure | 4 |
Others | 2 |